Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia
NCT04414930Phase 2Completed
- Sponsor
- University of California, San Diego
- Start
- Nov 2020
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of adenosine-5′-monophosphate in schizophrenia, schizoaffective disorder, sponsored by University of California, San Diego. Started Nov 2020; status: completed.
02
Drugs
adenosine-5′-monophosphate
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT04414930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04414930.